olopatadine / Generic mfg. - LARVOL DELTA

Comprehensive Analytical Investigation of the Photodegradation of Olopatadine and In Silico Toxicity Assessment of Its Photodegradation Products. (PubMed, Molecules) - "Five products were predicted to exhibit reproductive toxicity and irritation potential, whereas one compound showed a potential tumorigenic risk. Overall, this study provides comprehensive insight into the photostability of OLO and the formation of its photodegradation products."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials."

Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Viscosity modeling of propyl butanoate and 2-alkanol mixtures using modified Cohen-Turnbull and UNIFAC-VISCO approaches. (PubMed, Sci Rep) - "This parameter exhibited an increasing trend with increasing alcohol chain length (0.048 for 2-propanol to 0.084 for 2-hepatanol). Both models effectively eliminated systematic bias (|bias| < 0.5%), with the M-ECTM performing marginally better for longer-chain alcohols and the EFVC-UNIFAC demonstrating superior statistical efficiency. These results establish that the M-ECTM is optimal for maximum precision, whereas the EFVC-UNIFAC offers an excellent compromise between accuracy and parsimony for engineering applications involving ester-alcohol mixtures."

Journal • Addiction (Opioid and Alcohol)

Blood–brain barrier permeability of antihistamines and risk of depression in children and adolescents: a real-world cohort study (CINP 2026) - "Exposure groups were defined by antihistamine BBB permeability: the low-BBB cohort (fexofenadine, bilastine, ebastine, olopatadine, acrivastine) and the high-BBB cohort (diphenhydramine, chlorpheniramine, hydroxyzine, promethazine, doxylamine, triprolidine, pheniramine). This large-scale, real-world analysis suggests that high-BBB-penetrant antihistamines may confer an elevated risk of depression in children and adolescents with allergic rhinitis. The absence of associations for negative-control outcomes supports the internal validity of this finding and implicates BBB permeability as a plausible factor influencing psychiatric vulnerability. Clinically, these results highlight the importance of considering BBB penetrability when selecting antihistamines for pediatric patients, particularly those with emotional or behavioral risk factors."

Clinical • Real-world • Real-world evidence • Acne Vulgaris • Allergic Rhinitis • CNS Disorders • Depression • Immunology • Inflammation • Mental Retardation • Mood Disorders • Psychiatry

Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma (EAACI 2026) - "To evaluate and compare the effect of a fixed‑dose olopatadine hydrochloride/mometasone furoate intranasal spray versus intranasal mometasone furoate monotherapy on AR and BA control in children...Both regimens showed a favourable safety profile. Conclusion Intranasal MF and the fixed‑dose OLO/MF combination improve AR and concomitant BA control without escalation of baseline asthma therapy, with OLO/MF providing a more pronounced clinical, functional and anti‑inflammatory benefit and representing a promising option for children with moderate‑to‑severe AR and comorbid BA."

Clinical • Late-breaking abstract • Allergic Rhinitis • Immunology • Inflammation

Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens (EAACI 2026) - "These AEs were deemed non-serious and did not require additional therapy. Conclusion Mometasone+olopatadine nasal spray has demonstrated high efficacy and safety in patients with hypersensitivity to epidermal allergens under conditions of continuing exposure to a causal allergen."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Open-Label Clinical Trial To Evaluate The Effect Of Intranasal Olopatadine/Mometasone And Azelastine/Mometasone On Histamine Reactivity In Skin Prick Tests (EAACI 2026) - "Conclusion Intranasal antihistamines exert a measurable suppressive effect on histamine-induced skin and sensory responses that persists beyond the dosing period. A washout interval of approximately five days is recommended before performing skin testing in patients treated with intranasal azelastine or olopatadine"

Clinical • Allergic Rhinitis • Allergy • Immunology • Inflammation

Advances in the management of allergic rhinitis: clinical relevance of the mometasone furoate-olopatadine association and the challenge of patient self-diagnosis and self-treatment. (PubMed, Drugs Context) - "Clinical trials demonstrate superior improvement of nasal and ocular symptoms, faster onset of action, and favourable long-term safety compared with monotherapies. Its single-device formulation may enhance adherence and reduce inappropriate polypharmacy, offering a practical, guideline-aligned option for optimizing management of allergic rhinitis and mitigating risks associated with patient self-treatment."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation

Development and Characterization of Olopatadine and Verbascoside Loaded Thermoresponsive In Situ Gels for Ocular Drug Delivery: A Factorial Design Approach for Allergic Conjunctivitis. (PubMed, Drug Dev Ind Pharm) - "Mathematical analysis of the release kinetics revealed a good fit with the Weibull model. No adverse effects were observed in rats during Draize's in vivo test.ConclusionsConsequently, the drug-loaded in situ gel formulation may be a promising option for treating allergic conjunctivitis."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Effects of centrally administered histamine on the rat micturition reflex (AUA 2026) - "In some rats, effects of icv pretreated olopatadine (olo, H1 antagonist, 3 or 10 nmol/rat), zolantidine (zol, H2 antagonist, 10 or 30 nmol/rat), MK-801 (NMDA antagonist, 30 nmol/rat) or DNQX (AMPA antagonist, 0.3 or 1 nmol/rat) on the histamine (3 µg/rat, icv)-induced responses were examined. Centrally administered histamine induces facilitation of the rat micturition via brain H1, H2 and AMPA receptors, indicating that brain histamine receptors might be new therapeutic targets for neurogenic bladder overactivity."

Preclinical • Reflex

GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. (PubMed, Circulation) - "Restoration of GPRASP1 expression or pharmacological inhibition of ASNS activity with olopatadine normalized aspartate utilization, improved mitochondrial bioenergetics, rescued endothelial function, and attenuated cardiopulmonary pathology in PH-HFpEF models. Our findings unlocked a noncanonical role of GPRASP1 in preserving pulmonary endothelial homeostasis and delineated a novel GPRASP1-PRKN-ASNS axis that connected proteostasis with endothelial metabolic integrity, highlighting aspartate metabolism as a targetable vulnerability in cardiopulmonary disease."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Inflammation • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Targeted Protein Degradation • ASNS

Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts. (PubMed, Allergy) - "There is an important across-country and across-class variability in terms of costs of allergic rhinitis medications. The results of this study will inform the ARIA-EAACI 2024-2025 guidelines."

Journal • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Cohort Study of Pregnancy Outcomes After Exposure to Fexofenadine or Olopatadine in the First Trimester. (PubMed, Congenit Anom (Kyoto)) - "This study found no evidence that exposure to fexofenadine or olopatadine in the first trimester increases the risk of major birth defects. These second-generation antihistamines appear to be relatively safe in pregnant women with allergic conditions."

Journal • Allergy

Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. (PubMed, Braz J Otorhinolaryngol) - P2, P3 | "This pooled analysis demonstrated the superiority of Olo/Mom compared to its monotherapy constituents or placebo in reducing SAR symptoms over 14-days. Moreover, this study showed that Olo/Mom has a rapid onset of action and significantly improves RQLQ scores compared to placebo. Administration of Olo/Mom BID is an effective and well-tolerated option for the treatment of SAR in patients aged 12-years or older."

Journal • Retrospective data • Allergic Rhinitis • Immunology • Inflammation

A red-eye presentation concerning for vernal keratoconjunctivitis: a case report. (PubMed, Allergy Asthma Clin Immunol) - "VKC is uncommon in Canada, but may lead to vision-threatening complications if a patient is not appropriately seen by an ophthalmologist and it goes unrecognized. It should be considered in cases of conjunctivitis that are unresponsive to antihistamines, even when seasonal patterns or allergen sensitization are unclear. Topical and oral antihistamine combination is effective in stabilizing VKC symptoms, with the addition of topical steroids if needed for flares. VKC treatment can require a prolonged course."

Journal • Allergy • Conjunctivitis • Dermatology • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus

Does ACE2 deficiency have a role in Parkinson's disease -exacerbated pulmonary fibrosis? (PubMed, Exp Neurol) - "ROC analysis validated hub genes (e.g., BDNF, FOSL2) with good diagnostic value (AUC > 0.7), and molecular docking identified Smilagenin, Fostamatinib, Olopatadine, and Amlexanox as potential therapeutics. This study confirms ACE2 deficiency is a central driver of PD-exacerbated pulmonary fibrosis via the FoxO1/TNF/JAK1-STAT3/AGE-RAGE pathways, providing novel biomarkers and drug candidates to address the clinical need for managing this comorbidity."

Journal • CNS Disorders • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Movement Disorders • Parkinson's Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • BDNF • FOSL2 • JAK1 • TGFB1

Effects of olopatadine hydrochloride on substance P concentrations in nasal secretions and nasal symptoms. (PubMed, World J Exp Med) - "Olopatadine suppresses release of SP, which is involved in itching and inflammation. Our findings suggest that its administration may prove to be a useful new strategy for treating allergies."

Clinical • Journal • Allergic Rhinitis • Allergy • Dermatology • Immunology • Inflammation • Otorhinolaryngology

Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. (PubMed, World Allergy Organ J) - "Patients with moderate-to-severe allergic rhinitis (AR) often experience a heavy clinical burden and require more medications to alleviate nasal symptoms. Treatment-emergent adverse events (TEAEs) occurred in 11.2%, 13.5%, and 11.3% of patients in the GSP301, OLO, and MF groups, respectively. Compared with OLO and MF, GSP301 demonstrated superior efficacy, safety, and potential advantages in alleviating local inflammation in patients with moderate-to-severe SAR."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study. (PubMed, Br J Clin Pharmacol) - "In this large nationwide cohort of patients with allergic rhinitis, second-generation antihistamines with higher vs. lower sedative potential showed no difference in injury risk during Japan's pollen season."

Journal • Retrospective data • Allergic Rhinitis • Anesthesia • Immunology • Inflammation

Comparative Effects of Anti-Inflammatory Therapies on Olfactory Bulb Histopathology and Olfactory Function in a Rat Model of Experimental Allergic Rhinitis. (PubMed, J Inflamm Res) - "All treatment modalities improved olfactory mucosal and olfactory bulb histopathological parameters, with no clear superiority. Notably, methylprednisolone and olopatadine provided early improvement in olfactory function, highlighting their therapeutic potential."

Journal • Preclinical • Allergic Rhinitis • Immunology • Inflammation

Efficacy of 0.05% Cyclosporine Eye Drops in the Treatment of Allergic Conjunctivitis-Associated Dry Eye in Children (ChiCTR) - P4 | N=72 | Not yet recruiting | Sponsor: Beijing Childrens Hospital,Capital Medical University; Beijing Childrens Hospital,Capital Medical University

New P4 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

A Clinical Study on the Effect of Topical Anti-Allergic Eye Drops on Skin Prick Test Results in Patients with Allergic Rhinoconjunctivitis (ChiCTR) - P=N/A | N=180 | Not yet recruiting | Sponsor: Meishan City Peoples Hospital; Meishan City Peoples Hospital

New trial • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Gland Pharma Limited (Gland)…has received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) filed for olopatadine hydrochloride ophthalmic solution USP, 0.7% (OTC). (CNBC-TV18) - "It is indicated for the treatment of ocular itching associated with allergic conjunctivitis, offering patients an effective over-the-counter option for relief from allergy-related eye symptoms."

ANDA • Allergy • Ophthalmology

Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review. (PubMed, Front Allergy) - "After oral compound glycyrrhizin, olopatadine hydrochloride, triprolidine hydrochloride, and topical pimecrolimus for a week, his facial lesions were completely cleared. No recurrence of similar rash or other adverse effects was observed during the subsequent follow-up period over 5 months. It is concluded that eczema could be induced temporarily by secukinumab, and maybe continued application."

Journal • Alopecia • Atopic Dermatitis • Dermatology • Immunology • Psoriasis • Pyoderma Gangrenosum • Sarcoidosis • IL17A

Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions. (PubMed, Clin Pharmacol Drug Dev) - "No serious adverse events occurred, and safety profiles were comparable between formulations. This research confirmed the bioequivalence and similar safety of the generic olopatadine hydrochloride tablets to the reference formulation."

Journal